Endocrinology, Vol 118, 2312-2318, Copyright © 1986 by Endocrine Society

ARTICLES

Processing of angiotensin II (A-II) and (Sar1,Ala8)A-II by cultured bovine adrenocortical cells

A Crozat, A Penhoat and JM Saez

Bovine adrenocortical cells, cultured in a chemically defined medium, were used to study the fate of [125I] iodoangiotensin II ([125I]iodo-A- II) and its antagonist (Sar1,Ala8)A-II ([125I]iodo-Saralasin). The binding of both ligands was time and temperature dependent. The maximum specific binding at 37 C, which was reached within 1 h, was followed by a decline with a half-life of about 2 h and 8 h for [125I]iodo-A-II and [125I]iodo-Saralasin, respectively. The decrease of the specific binding was parallel to the appearance in the medium of degraded ligand. At 4 C, the binding of [125I]iodo-A-II was stable for 12 h and no degradation of ligand occurred. Under several experimental conditions, about 70% of the total [125I]iodo-A-II bound was internalized, whereas, in the case of [125I]iodo-Saralasin, less than 25% of the total bound ligand was internalized. These differences in the binding kinetics between A-II and its antagonist were mainly the differences in the rate of internalization of the bound ligands, more rapid for [125I]iodo-A-II (t1/2 approximately equal to 10 min) than for [125I]iodo-Saralasin (t1/2 = 90 min). On the other hand, the rate of degradation of internalized ligand was similar for both ligands (t1/2 = 15 min). Ionophore monensin enhanced the total cellular uptake of both ligands by increasing the amount of internalized ligands. Monensin did not modify the rate of internalization of the two ligands but markedly decreased their rate of degradation (t1/2 approximately equal to 60 min). These results indicate that both A-II and its antagonist are internalized and degraded by adrenocortical cells, but the rate of internalization of the antagonist is lower than that of the agonist. They also show that receptor-mediated endocytosis is the main pathway by which A-II is rapidly degraded by adrenocortical cells. Since A-II receptors are present in many tissues, the receptor-mediated degradation could explain the very short half-life in plasma of this hormone.

This article has been cited by other articles:

				T. Takezako, C. Gogonea, Y. Saad, K. Noda, and S. S. Karnik "Network Leaning" as a Mechanism of Insurmountable Antagonism of the Angiotensin II Type 1 Receptor by Non-peptide Antagonists J. Biol. Chem., April 9, 2004; 279(15): 15248 - 15257. [Abstract] [Full Text] [PDF]

				A. SPAT and L. HUNYADY Control of Aldosterone Secretion: A Model for Convergence in Cellular Signaling Pathways Physiol Rev, April 1, 2004; 84(2): 489 - 539. [Abstract] [Full Text] [PDF]

				J. G. Modrall, M. Nanamori, J. Sadoshima, D. C. Barnhart, J. C. Stanley, and R. R. Neubig ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling Am J Physiol Cell Physiol, September 1, 2001; 281(3): C801 - C809. [Abstract] [Full Text] [PDF]

				S. Miserey-Lenkei, Z. Lenkei, C. Parnot, P. Corvol, and E. Clauser A Functional Enhanced Green Fluorescent Protein (EGFP)-Tagged Angiotensin II AT1A Receptor Recruits the Endogenous G{{alpha}}q/11 Protein to the Membrane and Induces Its Specific Internalization Independently of Receptor- G Protein Coupling in HEK-293 Cells Mol. Endocrinol., February 1, 2001; 15(2): 294 - 307. [Abstract] [Full Text]

				C. Le Roy, J. Y. Li, D. M. Stocco, D. Langlois, and J. M. Saez Regulation by Adrenocorticotropin (ACTH), Angiotensin II, Transforming Growth Factor-{beta}, and Insulin-Like Growth Factor I of Bovine Adrenal Cell Steroidogenic Capacity and Expression of ACTH Receptor, Steroidogenic Acute Regulatory Protein, Cytochrome P450c17, and 3{beta}-Hydroxysteroid Dehydrogenase Endocrinology, May 1, 2000; 141(5): 1599 - 1607. [Abstract] [Full Text] [PDF]

				L. M. de Lannoy, A.H. J. Danser, A. M.B. Bouhuizen, P. R. Saxena, and M. A.D.H. Schalekamp Localization and Production of Angiotensin II in the Isolated Perfused Rat Heart Hypertension, May 1, 1998; 31(5): 1111 - 1117. [Abstract] [Full Text] [PDF]

				B. N. Becker, H.-F. Cheng, and R. C. Harris Apical ANG II-stimulated PLA2 activity and Na+ flux: a potential role for Ca2+-independent PLA2 Am J Physiol Renal Physiol, October 1, 1997; 273(4): F554 - F562. [Abstract] [Full Text] [PDF]

				J. P. van Kats, L. M. de Lannoy, A. H. J. Danser, J. R. van Meegen, P. D. Verdouw, and M. A. D. H. Schalekamp Angiotensin II Type 1 (AT1) Receptor–Mediated Accumulation of Angiotensin II in Tissues and Its Intracellular Half-life In Vivo Hypertension, July 1, 1997; 30(1): 42 - 49. [Abstract] [Full Text]

				R. Ouali, M.-C. Berthelon, M. Begeot, and J. M. Saez Angiotensin II Receptor Subtypes AT1 and AT2 Are Down-Regulated by Angiotensin II through AT1 Receptor by Different Mechanisms Endocrinology, February 1, 1997; 138(2): 725 - 733. [Abstract] [Full Text] [PDF]

				W. G. Thomas, K. M. Baker, T. J. Motel, and T. J. Thekkumkara Angiotensin II Receptor Endocytosis Involves Two Distinct Regions of the Cytoplasmic Tail J. Biol. Chem., September 22, 1995; 270(38): 22153 - 22159. [Abstract] [Full Text] [PDF]